Leading innovative healthcare solutions-providing company Halberd Corporation (OTCMKTS:HALB) has been engaged in research and development activities for quite a while.

More importantly, the company has also managed to make a number of major breakthroughs and one of those was achieved last month. Back on February 13 this year the company announced that it had been successful in having a significant breakthrough in developing a treatment for Candida auris infections. It should be noted that the company had been sent a sample of the Candida auris pathogen by the Centers for Disease Control and Prevention (CDC) as part of the group of antibiotic-resistant pathogens that were to be tested by the company.

The company’s scientific partner in the exercise is Youngstown State University and in this collaboration, the company came up with an innovative way to use its proprietary extracorporeal method to successfully eradicate the pathogen. The company had deployed its technology on other pathogens as well and had managed to eliminate E. Coli and gram-negative bacteria as well.

In this context, it ought to be kept in mind that Candida auris is one of the leading public health threats at this point in time and is known for being resistant to a range of medicines. Additionally, it is a pathogen that can lead to high mortality rates as well.

The CDC noted earlier in the month that Candida auris had emerged as an ‘urgent threat’ after it had completed a new study in which it was revealed that it was spreading at a worrying rate in healthcare facilities. It had first been reported back in 2016 but it spread at an alarming rate from 2020 to 2021 and on top of that 1 out of 3 patients infected with it end up deceased. Hence, the breakthrough from Halberd was a significant one.